

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

RESIGNATION OF DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of HBM Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) announces that Dr. Atul Mukund Deshpande (“**Dr. Deshpande**”) has tendered his resignation as an executive Director of the Company with effect from 25 April 2021 for the reason of seeking other opportunities in his career development.

Dr. Deshpande has confirmed that he has no disagreement with the Board except that Dr. Deshpande and the Company are having ongoing discussions to finalize details of the restricted shares granted to Dr. Deshpande pursuant to pre-IPO share incentive plan of the Company. There is no other matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude to Dr. Deshpande for his valuable contribution to the Company during his tenure of office.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman

Hong Kong, 25 April 2021

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Mai-Jing Liao as executive Directors; Mr. Yu Min Qiu and Mr. Junfeng Wang as non-executive Directors; and Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Ms. Weiwei Chen as independent non-executive Directors.